GDTC News & Events

CytoMed Therapeutics issued a statement to address recent statements containing "inaccurate and misleading" claims regarding the Company's research programs, clinical progress, and operations.The company said, " CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company's scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress. CytoMed's research is focused on CAR gammadelta T cell therapies and iPSC-derived gammadelta NKT cell therapies, based on established immunological science. The Company's lead CAR gammadelta T cell program has received regulatory approval to proceed with a first-in-human clinical trial, which is currently ongoing at National University Hospital, Singapore. This clinical activity is conducted in accordance with applicable regulatory and ethical requirements. Other programs, including iPSC-derived gammadelta NKT cell candidates, remain in preclinical development. CytoMed does not claim that any of its therapeutic candidates are approved for commercial use or clinically validated beyond their current stage of development. Assertions regarding CytoMed's regulatory status, manufacturing capabilities, governance, or financial transparency that contradict the above facts are inaccurate or taken out of context and designed to affect the Company's share price. The Company operates in compliance with applicable regulations and follows development practices appropriate for its stage. CytoMed remains committed to advancing its pipeline responsibly and to communicating accurate, timely information through official Company disclosures. The Company reserves the right to take appropriate action to address the dissemination of false or misleading information that may adversely affect its reputation or stakeholders."

CytoMed Therapeutics updates shareholders as the company enters a new year in 2026. The company said, "As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural Killer cells. In so doing, it will enhance access to rare and valuable cord blood as sources for cell-based allogeneic therapies. In addition to CytoMed's gamma delta T cells, Natural Killer cells also express receptors that recognise stress ligands, allowing them to be cytotoxic tools to combat a wide variety of solid and hematological cancers. Notably, CytoMed's efforts in development of Natural Killer cell therapy has recently received support from Enterprise Singapore, a Singapore government agency championing enterprise development. For this new year 2026, the Company believes it has enough resources to continue funding its activities for at least a year given our low-cost infrastructure in Southeast Asia. Besides the usual capital market routes, CytoMed can look to licencing and asset monetisation from real estate properties which it owns and uses for operation. We are also continuously exploring proposals with sustainable benefits as we explore with long-term strategic partners including synergistic biotechs and hospitals which can strengthen the business and international aspects with less dilution. Notably CytoMed was ranked 4 out of 5 points in terms of investment potential in 2025 December's Morning Star publication. As a matter of full disclosure, our Chairman Peter Choo intends to increase his shareholding in the Company and will make the relevant announcement as soon as possible. As announced on December 8, 2025, CytoMed has entered into a Memorandum of Understanding with Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed's patented allogeneic unmodified Gamma Delta T cells for no-option cancer patients in Malaysia. We target to submit an Investigational New Drug application to the Malaysian authorities before June this year. This initiative complements CytoMed's ongoing first-in-human Phase I chimeric antigen receptor T cell clinical trial at National University Hospital Singapore, which uses gammadelta T cells modified to express a CAR targeting various cancer types, including advanced colorectal cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, hepatocellular carcinoma. To date, six patients had been treated at two dosage levels in Singapore. Unmodified gamma delta T cells have been demonstrated in international clinical trials to have potential to kill cancer cells including brain cancers. CytoMed is co-author in a recent September/October 2025 publication of a preclinical study, in a research article entitled "Donor-Derived Vgamma9Vdelta2 T Cells for Acute Myeloid Leukemia: A Promising "off-the-shelf" Immunotherapy Approach". The study results from this collaborative research with The University of Texas, MD Anderson Cancer Center, are suggesting the great potential of CytoMed's allogeneic gammadelta T cell therapy for treating acute myeloid leukemia. This collaboration with MDACC is under a previously announced research agreement in May 2023. The research article is now publicly and freely online at Donor-Derived Vgamma9Vdelta2 T Cells for Acute Myeloid Leukemia: A Promising "Off-the-Shelf" Immunotherapy Approach."

CytoMed Therapeutics announced that it has entered into a Memorandum of Understanding, MoU, with Universiti Malaya Medical Centre, UMMC, a teaching hospital under Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed's patented allogeneic unmodified Gamma Delta T cells, CTM-GDT, for no-option cancer patients in Malaysia.

CytoMed Therapeutics (GDTC) announced that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology of TC BioPharm, a subsidiary of TC BioPharm (TCBP). This follows CytoMed's announcement on October 14, 2025 regarding its proposed acquisition of potentially synergistic assets from TCBL.